Acquisitions of patent applications should not receive blanket antitrust protections under the First Amendment, the Federal Trade Commission has argued as Amgen seeks to fend off allegations that it cornered the market for its blockbuster Enbrel arthritis drug.
Click on the "Follow" button below and you'll get the latest news from Global Competition Review via email, mobile or you can read them on your personal news page on this site.
You can unsubscribe anytime you want easily.
You can also choose the topics or keywords that you're interested in, so you receive only what you want.
Global Competition Review title: Global Competition Review